Christopher Lucas

Title: Christopher Lucas and Precision Cancer Drug Delivery.

Introduction

Christopher Lucas is an inventor based in Columbus, Ohio, and is associated with The Ohio State University. His work includes a patent application describing a DNA origami nanodevice designed to support personalized cancer treatment. The supplied information lists 1 patent.

Latest Patents

Lucas’s listed patent is “Multi-functional cancer drug delivery nanodevice for precision medicine.” It describes DNA origami nanostructures that can be functionalized for targeted drug delivery and personalized treatment. The structures are designed to enter cells through the endolysosomal pathway and help circumvent drug-resistance mechanisms in target cells.

The nanostructures can carry small-molecule drugs, including anthracyclines and antimetabolites, as well as nucleic acids such as antisense oligonucleotides, siRNA, and miRNA. They may also be combined with targeting or therapeutic antibodies directed at tumor-specific antigens, including CD33 and CD20. The approach is intended to be adaptable to different cancers and tailored to individual patients.

Career Highlights

The available information identifies Lucas’s association with The Ohio State University and his work on a nanotechnology-based approach to precision oncology. The patent describes a platform intended to combine drug delivery, molecular targeting, and patient-specific treatment design.

Collaborations

The supplied information names Carlos Castro and Patrick Halley as Lucas’s coworkers. Their connection to the described patent or project is not specified.

Conclusion

Christopher Lucas’s listed invention explores how DNA origami nanostructures could deliver cancer therapies with greater targeting and personalization, reflecting an effort to advance precision medicine.